Alliance Research — research payments reported

By program year

5 rows

Year	Kind	Amount	Payments
2023	Research	$50,493	1
2022	Research	$552	9
2021	Research	$750	15
2020	Research	$5,454	34
2019	Research	$28,679	6

Breakdown

Who paid Research payments · program years 2019–2023

Boehringer Ingelheim Pharmaceuticals, Inc. $50,493 1 payment
Supernus Pharmaceuticals, Inc. $28,679 6 payments
Takeda Pharmaceuticals U.S.A., Inc. $4,704 19 payments
Sunovion Pharmaceuticals Inc. $1,900 38 payments
AbbVie, Inc. $152 1 payment

Studies the money was for Research payments · program years 2019–2023

Proof of Concept and DRF with TRPC4 5 inhibitor in $50,493 1 payment
Evaluation of Spn-812 Er 200 and 400 MG Efficacy and Safety in Children With Adhd - A Double-Blind, Placebo-Controlled, Pivotal Trial $14,634 1 payment
Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of Spn-812 Er for the Treatment of Pediatric Patients With Attention Deficithyperactivity Disorder Adhd $8,327 3 payments
Evaluation of Spn-812 Er 400 and 600 MG Efficacy and Safety in Adolescents With Adhd - A Double-Blind, Placebo- Controlled, Pivotal Trial $5,718 2 payments
A Phase 4, Multicenter, 2-Part Study Composed of A 1-Year Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Active-Comparator, Dose-Optimization Evaluation Followed By A 1-Year Open-Label Evaluation to Assess the Safety and Efficacy of Guanfacine Hydrochloride Prolonged-Release (Spd503) in Children and Adolescents Aged 6 to 17 Years With Attention-Deficit/Hyperactivity Disorder $4,704 19 payments
A Clinical Trial to Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia $1,500 30 payments
A Clinical Trial to Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia $400 8 payments
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) $152 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.